Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

被引：11
|
作者：
Joly, V
Moroni, M
Concia, E
Lazzarin, A
Hirschel, B
Jost, J
Chiodo, F
Bentwich, Z
Love, WC
Hawkins, DA
Wilkins, EGL
Gatell, AJ
Vetter, N
Greenwald, C
Freimuth, WW
De Cian, W
机构：
[1] Hop Bichat, Dept Internal Med, F-75877 Paris 18, France
[2] Osped L Sacco, Div Infect Dis, Milan, Italy
[3] Osped San Raffaele, Div Infect Dis, Milan, Italy
[4] Pharmacia & Upjohn Co, Milan, Italy
[5] Osped S Orsola Malpighi, Div Infect Dis, Bologna, Italy
[6] Osped Borgo Roma, Div Infect Dis, Verona, Italy
[7] Hop Cantonal Univ Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland
[8] Universitatsspital Abt, Div Infect Dis, Zurich, Switzerland
[9] Kaplan Hosp, Clin Immunol, Rehovot, Israel
[10] Ruchill Hosp, Dept Infect & Trop Med, Glasgow G20 9NB, Lanark, Scotland
[11] Kolber Ctr, London, England
[12] N Manchester Grp Hosp, Dept Infect Dis, Manchester, Lancs, England
[13] Hosp Clin & Provencialo, Div Infect Dis, Barcelona, Spain
[14] Wiener Wald Pulm Zentrum Sanatorium, Dept Med, Vienna, Austria
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 11期
关键词：
D O I：
10.1128/AAC.44.11.3155-3157.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
引用
收藏
页码：3155 / 3157
页数：3
相关论文
共 50 条
  • [21] Prevalence of Drug Resistance in Human Immunodeficiency Virus Type 1-Infected Treatment-Naive Children in Pune, India
    Kumar, Mukesh
    Sen, Sourav
    Gupta, Rakesh K.
    Chaturbhuj, Devidas
    Tripathy, Srikanth P.
    Paranjape, Ramesh S.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (03) : 294 - 298
  • [22] Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients
    Dubois, V
    Dutronc, H
    Lafon, ME
    Poinsot, V
    Pellegrin, JL
    Ragnaud, JM
    Ferrer, AM
    Fleury, HJA
    JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (09) : 2288 - 2292
  • [23] Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
    Luzuriaga, K
    Bryson, Y
    Krogstad, P
    Robinson, J
    Stechenberg, B
    Lamson, M
    Cort, S
    Sullivan, JL
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (19): : 1343 - 1349
  • [24] Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors
    Maguire, M
    Shortino, D
    Klein, A
    Harris, W
    Manohitharajah, V
    Tisdale, M
    Elston, R
    Yeo, J
    Randall, S
    Xu, F
    Parker, H
    May, J
    Snowden, W
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 731 - 738
  • [25] High frequency of drug resistance mutations in human immunodeficiency virus type 1-infected Korean patients treated with HAART
    Sung, Heungsup
    Jung, You S.
    Kang, Moon W.
    Bae, In G.
    Chang, Hyun-Ha
    Woo, Jun H.
    Cho, Young K.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (10) : 1223 - 1229
  • [26] Different evolutionary patterns are found within human immunodeficiency virus type 1-infected patients
    Casado, C
    García, S
    Rodríguez, C
    del Romero, J
    Bello, G
    López-Galíndez, C
    JOURNAL OF GENERAL VIROLOGY, 2001, 82 : 2495 - 2508
  • [27] Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients
    Baqui, AAMA
    Meiller, TF
    Falkler, WA
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1999, 6 (06) : 808 - 811
  • [28] Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients
    Cruciani, M
    Gatti, G
    Mengoli, C
    Cazzadori, A
    Lazzarini, L
    Miletich, F
    Graziani, MS
    Malena, M
    Bassetti, D
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1077 - 1081
  • [29] A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children
    Sáez-Llorens, X
    Nelson, RP
    Emmanuel, P
    Wiznia, A
    Mitchell, C
    Church, JA
    Sleasman, J
    Van Dyke, R
    Richardson, CG
    Cutrell, A
    Spreen, W
    Hetherington, S
    PEDIATRICS, 2001, 107 (01)
  • [30] Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients
    Petrara, Maria Raffaella
    Cattelan, Anna Maria
    Zanchetta, Marisa
    Sasset, Lolita
    Freguja, Riccardo
    Gianesin, Ketty
    Cecchetto, Maria Grazia
    Carmona, Francesco
    De Rossi, Anita
    JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (03) : 195 - 200
12345